Geoffrey von Maltzahn

Geoffrey von Maltzahn, Ph.D. (born July 22, 1980) is an American biological engineer and entrepreneur in biotechnology and life sciences industry who has founded a number of companies including Indigo Agriculture, Sana Biotechnology, Kaleido Biosciences, Seres Therapeutics and Axcella Health.[1][2] He has 200 bioengineering and biotechnology patents and applications.[3][4][5][6]

Geoffrey von Maltzahn
BornJuly 22, 1980
NationalityAmerican
Alma materMassachusetts Institute of Technology (S.B., 2003)
University of California, San Diego (M.S., 2005)
Massachusetts Institute of Technology (Ph.D. 2010)
Known forMicrobiome therapeutics, microbiome agriculture, communicating nanoparticles
AwardsLemelson-MIT Student Prize (2009)
National Inventors Hall of Fame Collegiate Inventors Competition Graduate Prize (2009),
Massachusetts Institute of Technology Randolph G Wei Award (2003)
Scientific career
FieldsMicrobiome, Microbiology, Nanotechnology, Microbiome Agriculture, Synthetic Biology
Academic advisorsSangeeta N. Bhatia, Shuguang Zhang

Early life and education

Geoffrey von Maltzahn was born in Arlington, Texas, and subsequently moved to Alexandria, Virginia where he graduated from Thomas Jefferson H.S. for Science and Technology. He was awarded his B.S. in Chemical Engineering from the Massachusetts Institute of Technology (MIT) in 2003, his Master of Science degree in Bioengineering from the University of California, San Diego in 2005, and his PhD from the Harvard–MIT Division of Health Sciences and Technology at the Massachusetts Institute of Technology in 2010.[7][8]

Career

In 2009, Geoffrey von Maltzahn joined Flagship Pioneering, where he focuses on inventing and building new life science companies. In the same year, he co-founded Axcella Health, a company focused on developing amino acid therapeutics. In 2010, he co-founded Seres Therapeutics[9] and served as the Chief Technology Officer.[10][11] In 2013, he co-founded Indigo Agriculture, a company focused on improving the microbiome of modern crops and is currently Chief Innovation Officer.[12] In 2015, he founded Kaleido Biosciences, is a clinical-stage biotechnology company engaged in the development of the microbiome. Until 2017, he served as the CEO of the company.

Awards and recognitions
gollark: Well, yes, it isn't perfect, through broadly speaking I think stuff like people not getting food is more down to people not caring than the structure of society.
gollark: And yet we have a mostly functioning system which produces mostly enough food, and is able to make the mind-breakingly complex supply chains for that food work.
gollark: Pretty much everything we actually produce is in the "not entirely necessary but nice to have" box.
gollark: There is lots of stuff which nobody really *needs* - you can live without it, society could work without it (if we had set stuff up that way) - but it's not very nice to not have it. Like computers, or modern medicine, or non-bare-minimum food and housing.
gollark: Food is, broadly speaking, necessary to live. But while I could probably *survive* on cheaper, less resource-intensive-to-produce food than I do, or less food by caloric content and stuff, I like to have more/better food than is strictly necessary. Same with water - I won't die of dehydration on some small amount per day, but on the whole I'll be worse off if I don't have as much to drink as I want, or enough water for showering and washing stuff.

See also

Indigo Agriculture
David Perry

References
  1. Meet the 30 biotech leaders under 40 who are searching for breakthrough treatments and shaping the future of medicine Business Insider Retrieved 9 October 2017
  2. "Former Juno execs unveil Sana, a new cell engineering biotech that's reportedly raising more than $800M". GeekWire. January 7, 2019.
  3. Patents by Inventor Geoffrey von Maltzahn Justia Patents
  4. Patents as Early Indicators of Technology and Investment Trends Frontiers - figure 3 Retrieved 20 June 2018
  5. Geoffrey von Maltzahn at Bloomberg Bloomberg
  6. Flagship Pioneering Unveils Kaleido Biosciences and First Chemistry Platform for Microbiome Health Market Insider Retrieved 18 September 2017
  7. Geoffrey von Maltzahn MIT
  8. Geoffrey von Maltzahn at Bloomberg Bloomberg
  9. Term Sheet Fortune Retrieved 21 July 2016
  10. Seres Therapeutics IPO Soars, Raises $133 Million Investors Business Daily Retrieved 26 June 2015
  11. Seres at Crunchbase Crunchbase
  12. Indigo Agriculture on CNBC CNBC
  13. "30 Under 40 Leaders in Biotech Pharma 2017". 2017-10-09. Retrieved 2017-10-09.
  14. "MSNBC's Inventions of the Year". 2009-11-10. Retrieved 2017-10-09.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.